Department of Rheumatology, University Mohammed V Souissi, Faculty of Medicine and Pharmacy, El Ayachi hospital, University Hospital of Rabat-Sale, PO Box: 10000, Sale, Morocco.
BMC Musculoskelet Disord. 2013 Apr 26;14:147. doi: 10.1186/1471-2474-14-147.
Metabolic syndrome, a cluster of classical cardiovascular risk factors, including hypertension, obesity, glucose intolerance, and dyslipidemia is highly prevalent in patients with rheumatoid arthritis (RA). The aim of the study was to assess the frequency of metabolic syndrome (MS) in RA patients, and to evaluate the relationships between metabolic syndrome and RA.
The study was conducted on 120 RA patients according to the 1987 revised American College of Rheumatology classification criteria, and 100 age and sex matched apparently healthy controls. The frequency of metabolic syndrome was assessed using six Metabolic Syndrome definitions (Joint Consensus 2009, National Cholesterol Education Programme 2004 and 2001, International Diabetes Federation, World Health Organisation and European Group for Study of Insulin Resistance). Logistic regression was used to identify independent predictors of metabolic Syndrome.
The frequency of metabolic syndrome varied from 18 to 48.6% in RA according to the definition used and was significantly higher than controls (for all definitions p<0.05). In multivariate analysis, higher ESR was independently associated with the presence of Met S (OR =1.36; CI: 1.18-2.12; p = 0.03). Glucocorticoid use, but not other disease modifying anti-rheumatic drugs (DMARDs), values remained significant independent predictors of the presence of metabolic syndrome in RA patients (OR = 1.45; CI: 1.12-2.14; p = 0.04).
In summary, the frequency of metabolic syndrome in RA varies according to the definition used and was significantly higher compared to controls (for all definitions p<0.05). Higher systemic inflammatory marker, and glucocorticoids use were independent predictors associated with the presence of metabolic syndrome in patients with RA. These findings suggest that physicians should screen for metabolic syndrome in patients with RA to control its components and therefore reduce the risk of cardiovascular disease in these patients.
代谢综合征是一组常见的心血管危险因素,包括高血压、肥胖、葡萄糖耐量异常和血脂异常,在类风湿关节炎(RA)患者中非常普遍。本研究的目的是评估 RA 患者代谢综合征(MS)的频率,并评估代谢综合征与 RA 之间的关系。
根据 1987 年修订的美国风湿病学会分类标准,对 120 例 RA 患者进行研究,并与 100 例年龄和性别匹配的明显健康对照者进行比较。采用六种代谢综合征定义(2009 年联合共识、2004 年和 2001 年国家胆固醇教育计划、国际糖尿病联合会、世界卫生组织和欧洲胰岛素抵抗研究组)评估代谢综合征的频率。采用 logistic 回归分析确定代谢综合征的独立预测因子。
根据使用的定义,RA 患者代谢综合征的频率从 18%到 48.6%不等,明显高于对照组(所有定义 p<0.05)。在多变量分析中,较高的 ESR 与代谢综合征的存在独立相关(OR=1.36;CI:1.18-2.12;p=0.03)。糖皮质激素的使用,但不是其他疾病修饰抗风湿药物(DMARDs),仍然是 RA 患者代谢综合征存在的独立预测因子(OR=1.45;CI:1.12-2.14;p=0.04)。
总之,RA 患者代谢综合征的频率因使用的定义而异,与对照组相比明显更高(所有定义 p<0.05)。较高的系统性炎症标志物和糖皮质激素的使用是与 RA 患者代谢综合征存在相关的独立预测因子。这些发现表明,医生应在 RA 患者中筛查代谢综合征,以控制其成分,从而降低这些患者患心血管疾病的风险。